sr141716 has been researched along with cannabidivarin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bräse, S; Gläser, F; Müller, CE; Nieger, M; Rempel, V; Volz, N | 1 |
| Duncan, M; Parker, LA; Rock, EM; Sticht, MA; Stott, C | 1 |
2 other study(ies) available for sr141716 and cannabidivarin
| Article | Year |
|---|---|
Antagonists for the orphan G-protein-coupled receptor GPR55 based on a coumarin scaffold.
Topics: Allosteric Site; Animals; CHO Cells; Coumarins; Cricetinae; HEK293 Cells; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Receptors, Cannabinoid; Receptors, G-Protein-Coupled; Structure-Activity Relationship | 2013 |
Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats.
Topics: Animals; Behavior, Animal; Cannabinoid Receptor Agonists; Cannabinoids; Disease Models, Animal; Dronabinol; Drug Partial Agonism; Lithium Chloride; Male; Nausea; Phytochemicals; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant | 2013 |